Trial Profile
A Phase I/II Study of Gleevec Combined With Panitumumab (Vectibix) in Patients Prescreened for c-Kit/PDGFr Activated Pathways Using a Proteomic Based Assay.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Panitumumab
- Indications Cancer metastases; Colorectal cancer
- Focus Adverse reactions
- Acronyms NITMEC
- 23 Mar 2012 Actual patient number 10 added as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2010 Trial design presented as a poster at the 2010 annual meeting of the American Society of Clinical Oncology.